New anti-cancer strategies

Epigenetic therapies and biomarkers

Curtis Balch, John S. Montgomery, Hyun Il Paik, Sun Kim, Tim H M Huang, Kenneth Nephew

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Epigenetics is the study of chromatin modifications that affect gene expression without altering DNA nucleotide sequences. This review highlights a prominent role for epigenetic therapies, particularly those that reverse aberrant DNA methylation and histone acetylation, in the potential treatment of cancer. Administration of such therapies to reverse epigenetic "silencing" of tumor suppressors, including genes involved in chemotherapy responses, could prove useful in the management of cancer patients. In this review, we summarize recent advances in the use of methyltransferase and histone deacetylase inhibitors and possible synergistic combinations of these to achieve maximal tumor suppressor gene re-expression. Moreover, when used in combination with conventional chemotherapeutic agents, epigenetic-based therapies may provide a means to resensitize drug-resistant tumors to established treatments. As specific, aberrant epigenetic modifications are frequently associated with distinct cancer types, and likely occur early in tumorigenesis, these have potential utility as biomarkers. Finally, future directions are addressed, including alternative epigenetic targets, gene-specific modifications, and the use of bioinformatics.

Original languageEnglish
Pages (from-to)1897-1931
Number of pages35
JournalFrontiers in Bioscience
Volume10
Issue number2
StatePublished - 2005

Fingerprint

Biomarkers
Epigenomics
Tumors
Genes
Acetylation
Neoplasms
Histone Deacetylase Inhibitors
Chemotherapy
Bioinformatics
Tumor Suppressor Genes
Gene expression
Histones
Chromatin
Therapeutics
Nucleotides
Gene Expression
DNA
Methyltransferases
DNA Methylation
Computational Biology

Keywords

  • Bioinformatics
  • Biomarkers
  • Cancer
  • Chemosensitization
  • Chemotherapy
  • DNA Methylation
  • Drug Resistance
  • Epigenetic Biomarkers
  • Epigenetic Therapies
  • Epigenetics
  • HDAC
  • HDAC Inhibitor
  • Histone Deacetylase
  • Methylation
  • Methylation Biomarkers
  • Methyltransferase

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Balch, C., Montgomery, J. S., Paik, H. I., Kim, S., Huang, T. H. M., & Nephew, K. (2005). New anti-cancer strategies: Epigenetic therapies and biomarkers. Frontiers in Bioscience, 10(2), 1897-1931.

New anti-cancer strategies : Epigenetic therapies and biomarkers. / Balch, Curtis; Montgomery, John S.; Paik, Hyun Il; Kim, Sun; Huang, Tim H M; Nephew, Kenneth.

In: Frontiers in Bioscience, Vol. 10, No. 2, 2005, p. 1897-1931.

Research output: Contribution to journalArticle

Balch, C, Montgomery, JS, Paik, HI, Kim, S, Huang, THM & Nephew, K 2005, 'New anti-cancer strategies: Epigenetic therapies and biomarkers', Frontiers in Bioscience, vol. 10, no. 2, pp. 1897-1931.
Balch C, Montgomery JS, Paik HI, Kim S, Huang THM, Nephew K. New anti-cancer strategies: Epigenetic therapies and biomarkers. Frontiers in Bioscience. 2005;10(2):1897-1931.
Balch, Curtis ; Montgomery, John S. ; Paik, Hyun Il ; Kim, Sun ; Huang, Tim H M ; Nephew, Kenneth. / New anti-cancer strategies : Epigenetic therapies and biomarkers. In: Frontiers in Bioscience. 2005 ; Vol. 10, No. 2. pp. 1897-1931.
@article{f80c41bce2aa481782d1edf10df83b19,
title = "New anti-cancer strategies: Epigenetic therapies and biomarkers",
abstract = "Epigenetics is the study of chromatin modifications that affect gene expression without altering DNA nucleotide sequences. This review highlights a prominent role for epigenetic therapies, particularly those that reverse aberrant DNA methylation and histone acetylation, in the potential treatment of cancer. Administration of such therapies to reverse epigenetic {"}silencing{"} of tumor suppressors, including genes involved in chemotherapy responses, could prove useful in the management of cancer patients. In this review, we summarize recent advances in the use of methyltransferase and histone deacetylase inhibitors and possible synergistic combinations of these to achieve maximal tumor suppressor gene re-expression. Moreover, when used in combination with conventional chemotherapeutic agents, epigenetic-based therapies may provide a means to resensitize drug-resistant tumors to established treatments. As specific, aberrant epigenetic modifications are frequently associated with distinct cancer types, and likely occur early in tumorigenesis, these have potential utility as biomarkers. Finally, future directions are addressed, including alternative epigenetic targets, gene-specific modifications, and the use of bioinformatics.",
keywords = "Bioinformatics, Biomarkers, Cancer, Chemosensitization, Chemotherapy, DNA Methylation, Drug Resistance, Epigenetic Biomarkers, Epigenetic Therapies, Epigenetics, HDAC, HDAC Inhibitor, Histone Deacetylase, Methylation, Methylation Biomarkers, Methyltransferase",
author = "Curtis Balch and Montgomery, {John S.} and Paik, {Hyun Il} and Sun Kim and Huang, {Tim H M} and Kenneth Nephew",
year = "2005",
language = "English",
volume = "10",
pages = "1897--1931",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "2",

}

TY - JOUR

T1 - New anti-cancer strategies

T2 - Epigenetic therapies and biomarkers

AU - Balch, Curtis

AU - Montgomery, John S.

AU - Paik, Hyun Il

AU - Kim, Sun

AU - Huang, Tim H M

AU - Nephew, Kenneth

PY - 2005

Y1 - 2005

N2 - Epigenetics is the study of chromatin modifications that affect gene expression without altering DNA nucleotide sequences. This review highlights a prominent role for epigenetic therapies, particularly those that reverse aberrant DNA methylation and histone acetylation, in the potential treatment of cancer. Administration of such therapies to reverse epigenetic "silencing" of tumor suppressors, including genes involved in chemotherapy responses, could prove useful in the management of cancer patients. In this review, we summarize recent advances in the use of methyltransferase and histone deacetylase inhibitors and possible synergistic combinations of these to achieve maximal tumor suppressor gene re-expression. Moreover, when used in combination with conventional chemotherapeutic agents, epigenetic-based therapies may provide a means to resensitize drug-resistant tumors to established treatments. As specific, aberrant epigenetic modifications are frequently associated with distinct cancer types, and likely occur early in tumorigenesis, these have potential utility as biomarkers. Finally, future directions are addressed, including alternative epigenetic targets, gene-specific modifications, and the use of bioinformatics.

AB - Epigenetics is the study of chromatin modifications that affect gene expression without altering DNA nucleotide sequences. This review highlights a prominent role for epigenetic therapies, particularly those that reverse aberrant DNA methylation and histone acetylation, in the potential treatment of cancer. Administration of such therapies to reverse epigenetic "silencing" of tumor suppressors, including genes involved in chemotherapy responses, could prove useful in the management of cancer patients. In this review, we summarize recent advances in the use of methyltransferase and histone deacetylase inhibitors and possible synergistic combinations of these to achieve maximal tumor suppressor gene re-expression. Moreover, when used in combination with conventional chemotherapeutic agents, epigenetic-based therapies may provide a means to resensitize drug-resistant tumors to established treatments. As specific, aberrant epigenetic modifications are frequently associated with distinct cancer types, and likely occur early in tumorigenesis, these have potential utility as biomarkers. Finally, future directions are addressed, including alternative epigenetic targets, gene-specific modifications, and the use of bioinformatics.

KW - Bioinformatics

KW - Biomarkers

KW - Cancer

KW - Chemosensitization

KW - Chemotherapy

KW - DNA Methylation

KW - Drug Resistance

KW - Epigenetic Biomarkers

KW - Epigenetic Therapies

KW - Epigenetics

KW - HDAC

KW - HDAC Inhibitor

KW - Histone Deacetylase

KW - Methylation

KW - Methylation Biomarkers

KW - Methyltransferase

UR - http://www.scopus.com/inward/record.url?scp=17344367737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17344367737&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 1897

EP - 1931

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 2

ER -